| pubmed-article:8289991 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0030016 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0074554 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0683150 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:8289991 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:8289991 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8289991 | pubmed:dateCreated | 1994-2-22 | lld:pubmed |
| pubmed-article:8289991 | pubmed:abstractText | A few cases of severe rhabdomyolysis have been reported in heart transplant recipients treated simultaneously with ciclosporin (CS) and the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor lovastatin. When measured, plasma lovastatin HMG-CoA reductase inhibitor concentrations in these patients were higher than expected. This prompted us to study the plasma concentration profiles of simvastatin HMG-CoA reductase inhibitory activity after a single dose of simvastatin in kidney transplant recipients. Five patients treated with CS, azathioprine and prednisolone (CS patients) were compared to 5 patients treated with azathioprine and prednisolone (non-CS patients). The concentration curves had similar shapes but the mean area under the curve/24 h was almost 3 times higher (p = 0.047) and the mean peak concentration was twice as high in CS patients (p = 0.028). These results suggest a difference in the disposition of simvastatin in CS patients as compared to non-CS patients. Simvastatin should be administered in a reduced dosage to CS patients. | lld:pubmed |
| pubmed-article:8289991 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8289991 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8289991 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8289991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8289991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8289991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8289991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8289991 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8289991 | pubmed:issn | 0028-2766 | lld:pubmed |
| pubmed-article:8289991 | pubmed:author | pubmed-author:ThysellHH | lld:pubmed |
| pubmed-article:8289991 | pubmed:author | pubmed-author:KarkasJ DJD | lld:pubmed |
| pubmed-article:8289991 | pubmed:author | pubmed-author:ErikssonL OLO | lld:pubmed |
| pubmed-article:8289991 | pubmed:author | pubmed-author:ArnadottirMM | lld:pubmed |
| pubmed-article:8289991 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8289991 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:8289991 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8289991 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8289991 | pubmed:pagination | 410-3 | lld:pubmed |
| pubmed-article:8289991 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:meshHeading | pubmed-meshheading:8289991-... | lld:pubmed |
| pubmed-article:8289991 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8289991 | pubmed:articleTitle | Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. | lld:pubmed |
| pubmed-article:8289991 | pubmed:affiliation | Department of Nephrology, University Hospital, Lund, Sweden. | lld:pubmed |
| pubmed-article:8289991 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8289991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8289991 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8289991 | lld:pubmed |
